17 hrs ago
SeeThruEquity Issues Update on Harvard Bioscience Inc.
New York, NY / ACCESSWIRE / April 17, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update note on Harvard Bioscience Inc. regarding financial and operational results for Q4 2013 and FY 2013.
Regenerated Esophagus Successfully Transplanted Into Rat
A research team led by Paolo Macchiarini , MD, PhD at Karolinska Institutet in Sweden has successfully transplanted a regenerated esophagus into a rat using a bioreactor developed by Harvard Apparatus Regenerative Technology , a spin-off of Harvard Bioscience.
Harvard Bioscience Director David Green Sells 63,501 Shares
Harvard Bioscience Director David Green unloaded 63,501 shares of Harvard Bioscience stock on the open market in a transaction that occurred on Thursday, April 3rd.
The Motley Fool
I'm Selling Harvard Biosciences
Not bad. But the outlook for the parent company is not as rosy as I had expected, and my expectations were not that high to begin with.
Ruthigen IPO Set To Soar; Tetraphase To Find Lower Floor
Ruthigen's IPO provides strong investment opportunity based on relative valuations and addressing unmet market need with potential multi-billion dollar market.
Harvard Apparatus Regenerative Technology Spotlighted by Fast Company Co.Exist
Harvard Apparatus Regenerative Technology, Inc. , a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by Fast Company Co.Exist on March 19. The article, "Lab-Grown Organs Are Out In The Wild, And More Are Coming Soon," recounts the Company's ... (more)